share_log

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

SEC ·  Sep 13 16:07
Summary by Moomoo AI
Conduit Pharmaceuticals Inc., a Delaware-based company with a primary focus on pharmaceuticals, filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on September 13, 2024. This Pre-Effective Amendment No. 1 includes the filing of Exhibits 10.31 and 10.32, which amend Item 16 of Part II of the Registration Statement. The company, which is classified under the industrial code number 2834, has its principal executive offices located at 4995 Murphy Canyon Road, Suite 300, San Diego, CA. The amendment indicates that Conduit Pharmaceuticals plans to commence the sale of its securities to the public on a delayed or continuous basis after the registration statement becomes effective. The company is identified as a non-accelerated filer, a smaller reporting company, and an...Show More
Conduit Pharmaceuticals Inc., a Delaware-based company with a primary focus on pharmaceuticals, filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on September 13, 2024. This Pre-Effective Amendment No. 1 includes the filing of Exhibits 10.31 and 10.32, which amend Item 16 of Part II of the Registration Statement. The company, which is classified under the industrial code number 2834, has its principal executive offices located at 4995 Murphy Canyon Road, Suite 300, San Diego, CA. The amendment indicates that Conduit Pharmaceuticals plans to commence the sale of its securities to the public on a delayed or continuous basis after the registration statement becomes effective. The company is identified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. The prospectus, which constitutes Part I of the Registration Statement, remains unchanged by this amendment. The company has also detailed its indemnification policy for directors and officers, as well as recent sales of unregistered securities, including transactions with AstraZeneca and Nirland Limited. The estimated expenses for the issuance and distribution of the shares are approximately $90,000.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more